Insights on pharma trends and real-world AI applications in life sciences
Pharmato has completed its first funding round, led by Enbo Life Sciences. Proceeds will support core technology iteration, expansion of its pharmaceutical AI agent product matrix, large-scale validation of its virtual clinical trial platform, and building a multidisciplinary team. Founded in 2025, the company focuses on integrating virtual clinical trials and pharmaceutical AI agents into real-world drug development workflows. Its interactive, auditable, and continuously learning agent system covers trial design, site matching, enrollment prediction, endpoint assessment, and data quality management—positioned to augment professional judgment rather than replace medical and regulatory responsibility.
Moderna and Merck announced that the Phase III INTerpath-001 study of the individualized neoantigen mRNA therapy Intismeran Autogene (formerly mRNA-4157/V940) in combination with Keytruda for adjuvant treatment of patients with high-risk resected melanoma met its primary endpoints of recurrence-free survival (RFS) and distant metastasis-free survival (DMFS). The study was advanced based on the results of the prior KEYNOTE-942/mRNA-4157-P201 study, providing clinical rationale for further development of individualized neoantigen mRNA therapy in combination with PD-1 inhibitors in the adjuvant setting. Future market focus will center on the release of complete Phase III data, regulatory progress, and the expansion of this technology platform into other solid tumors.
Recently, Amylyx Pharmaceuticals announced positive topline results from the Phase 3 LUCIDITY clinical trial of its GLP-1 receptor antagonist Avexitide for the treatment of post-bariatric hypoglycemia (PBH). The study met its primary endpoint, with hypoglycemic events reduced substantially in the Avexitide group compared with placebo. Based on these results, the company plans to advance regulatory discussions and prepare for a potential marketing application.
In July 2026, Inc. announced the nomination of ISM9528 as a Preclinical Candidate Compound (PCC) for pain management. The molecule is a potential global first-in-class, cerebral, non-opioid oral small molecule inhibitor that targets Target Z, a new target identified by the AI platform PandaOmics. In preclinical studies, ISM9528 has demonstrated superior efficacy over standard therapies in a variety of pain models, even surpassing morphine in some models with excellent safety and pharmacokinetic characteristics. This is the 31st PCC nominated by Silicon Intelligence since 2021, once again validating the scale drug discovery capabilities of its AI platform.
Bayer is now weaving artificial intelligence deep into the core of its pharmaceutical and agricultural operations, aiming to break free from the traditional R&D constraints of lengthy timelines and towering costs. Drawing on publicly available data from official earnings reports, trusted industry media, and technology partners, this article examines five concrete, real-world AI deployments that have been independently cross-verified. In drug discovery, AI sifts through a massive library of 6 million compounds. By teaming up with Google Cloud's TPU-powered quantum computing, the company has accelerated virtual screening from tens of thousands of compounds per day to millions per day. In clinical trials, the ALYCE platform takes on the heavy lifting—automating the processing of up to 300,000 files and 1.6 terabytes of data from a single trial, while handling time-zone alignment and auto-correction along the way. In medical imaging, the Calantic® platform uses a "zero-click" workflow that frees radiologists from routine tasks, boosting their time spent on high-level diagnosis from just 10% to 65%. In smart agriculture, digital twin technology has shrunk a traditional 5-to-6-year breeding cycle down to an astonishing four months. And for internal operations, the DSO Go intelligent assistant went from concept to launch in just four months, supports nine languages, and drew 19,000 users in its first two months. For R&D professionals, this piece offers a clear technical breakdown and hard data to show that AI is no longer just about cutting costs or boosting efficiency—it is fundamentally reshaping how R&D itself is done.
On July 21, 2026, IMUNON today announced updated positive preliminary data from its ongoing Phase II minimal residual disease (MRD) conversion clinical trial of IMNN-001. The trial combines IMNN-001 with standard neoadjuvant and adjuvant chemotherapy (N/ACT) plus bevacizumab in women with newly diagnosed advanced ovarian cancer.
On July 16, 2026, global pharmaceutical giant Eli Lilly and Company announced a definitive agreement to acquire AtaiBeckley Inc., a clinical-stage biopharmaceutical company. Under the terms of the deal, Lilly will acquire all outstanding shares of AtaiBeckley for $6.75 per share in cash, representing an upfront equity value of approximately $2.8 billion.
At the 2026 Alzheimer’s Association International Conference (AAIC 2026), Biogen officially unveiled the full Phase 2 data from its CELIA study of Diranersen (BIIB080), a Tau-targeting antisense oligonucleotide (ASO) therapy. Following the previously reported topline results, this comprehensive disclosure provides systematic evidence across clinical endpoints, Tau biomarkers, and safety, marking one of the most significant clinical advancements in the Tau therapeutic field in recent years.
On July 10, 2026, Sanofi announced that the U.S. Food and Drug Administration (FDA) has officially approved the subcutaneous formulation Sarclisa Escena (isatuximab-irfc) for the treatment of patients with multiple myeloma (MM), covering all indications currently approved for the intravenous (IV) version of Sarclisa.
On July 9, 2026, clinical-stage biotechnology company Arialys Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational precision therapy, ART5803. This milestone marks a significant step forward for ART5803, the world’s first precision therapeutic candidate specifically designed to treat anti-NMDA receptor encephalitis (ANRE), fast-tracking its path toward regulatory review.
On July 8, 2026, the biopharmaceutical company Immunome announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for varegacestat (AL102), an innovative oral gamma-secretase inhibitor (GSI) for the treatment of adult patients with desmoid tumors.
On July 7, 2026, Compass Pathways announced the 26-week (6-month) follow-up results from COMP006, its second pivotal Phase 3 trial evaluating COMP360 (a synthetic formulation of psilocybin) for treatment-resistant depression (TRD). The data confirm that COMP360 maintains its previously reported rapid onset of effect while further validating the durability and reproducibility of its therapeutic benefit.
5 min